XML 63 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Deficit (Details Textual) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended
Dec. 12, 2018
Oct. 20, 2016
Dec. 28, 2018
Jul. 20, 2017
Nov. 30, 2018
Dec. 31, 2018
Nov. 30, 2018
Sep. 30, 2018
Dec. 31, 2017
Stockholders' Deficit (Textual)                  
Common stock authorized           100,000,000   100,000,000 100,000,000
Common stock, par value           $ 0.001   $ 0.001 $ 0.001
Common stock, shares issued           10,036,505   9,656,505 7,864,994
Common stock, shares outstanding           10,036,505   9,656,505 7,864,994
Preferred stock, par value           $ 0.001   $ 0.001 $ 0.001
Preferred stock, shares authorized           10,000,000   10,000,000 10,000,000
Purchase agreement, description         The Company issued and sold an aggregate of 170,000 additional Units to the Purchasers, for total gross proceeds to the Company of approximately $425,000 before deducting offering expenses.        
Aggregrate sale of shares               445,200  
Deducting offering expenses $ 1,538,000             $ 1,113,000  
Maximum offering, units               4,600,000  
Offering price, per share $ 2.50                
Warrant issued           144,005      
Risk free interest rate           2.85%   2.80% 1.90%
Expected stock price volatility           49.80%   49.80% 47.80%
Expected life of options (years)           4 years 7 months 13 days   5 years 5 years
Expected dividend yield           0.00%   0.00% 0.00%
Exercise price, per share           $ 2.75      
Liability           $ 5,535,570   $ 4,614,611 $ 5,286,596
Legal costs           $ 848,708   $ 833,470 $ 553,037
Acquired percentage       100.00%          
Aggregate shares issued of the then-outstanding NeuroOne shares       3,500,000          
Maximum Shares Issuable 615,200         170,000      
Brokerage commission           $ 73,000      
Paulson [Member]                  
Stockholders' Deficit (Textual)                  
Cash commission, percentage           12.00%      
Exercise price, per share           $ 2.75      
Common Stock [Member]                  
Stockholders' Deficit (Textual)                  
Net exchanges of shares                 859,976
Private Placement [Member]                  
Stockholders' Deficit (Textual)                  
Purchase agreement, description             (i) 1 share (each, a "Share") of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2018 Warrants").    
Maximum offering, units               4,000,000  
Offering price, per share               $ 2.50  
Warrant issued           50,520      
Cost of issuance           $ 59,694   $ 173,067  
Cash commission, percentage           10.00% 10.00%    
Exercise price, per share           $ 3.45 $ 3.45    
Common stock purchase price, per share           10.00% 10.00%    
Warrants exercisable, term               5 years  
Liability           $ 9,854   $ 26,878  
Legal costs           7,340   $ 62,389  
Brokerage commission           $ 42,500      
Warrant exercise price           $ 2.75      
Warrants are committed to be issued           66,520      
2019 Private Placement [Member]                  
Stockholders' Deficit (Textual)                  
Maximum offering, units           4,000,000      
Offering price, per share     $ 2.50     $ 2.50      
Warrant issued           134,048      
Risk free interest rate           2.53%      
Expected stock price volatility           49.80%      
Expected life of options (years)           5 years      
Expected dividend yield           0.00%      
Cost of issuance           $ 89,622      
Cash commission, percentage           12.00%      
Exercise price, per share           $ 3.00      
Common stock purchase price, per share           10.00%      
Warrants exercisable, term           5 years      
Liability           $ 13,875      
Legal costs           2,747      
Maximum Shares Issuable     160,000            
Gross proceeds from private placement     $ 400,000            
Maximum potential gross proceeds from financing           $ 10,000,000      
Warrant exercise price           $ 3.45      
Broker warrants issuable           16,000      
Warrants are committed to be issued           66,520      
Over-Allotment Option [Member]                  
Stockholders' Deficit (Textual)                  
Maximum offering, units               600,000  
Subsidiaries [Member]                  
Stockholders' Deficit (Textual)                  
Common stock, shares issued   5,131,514              
Maximum offering, units       4,000,000          
Exercise price, per share   $ 0.03              
Acquired percentage       100.00%          
Aggregate shares issued of the then-outstanding NeuroOne shares       6,291,994          
Net exchanges of shares       1,573,000          
Subscription receivable   $ 9,050